Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Research Award - Priority Announcement - HIV/AIDS and/or STBBI

Direct Payment

$105,000.00

Characterization of the clonal dynamics of HIV-specific T-cell repertoire from a phase 2b/3 HIV-vaccine efficacy trial

FY 2022-23

Summary
With an estimated 1.5 million new cases and 650 000 deaths globally in 2021, human immunodeficiency virus (HIV) infection is a major contributor to the global burden of disease and causes significant burden on healthcare systems in low-resource communities. As such, there is an urgent need for an effective HIV-preventative intervention. One of the major hurdles in HIV-vaccine development is that it is difficult to generate long-lived protective immunity, partly due to the extraordinary genetic diversity of different HIV strains. While the goal of many vaccines is to induce generation of protective antibodies, it has become increasingly clear induction of a strong and durable T-cell mediated response is also important for protection. As more early-stage studies and clinical trials shift back to the development of T-cell based preventative efforts, there is a need to leverage and develop more high-throughput and sensitive immunological approaches to study the vaccine elicited immune response. Using a smaller subset of vaccine participants from a phase 2b/3 HIV-vaccine efficacy trial that took place in Sub-Saharan Africa (HVTN705), this proposal will (1) aim to establish proof-of-concept that the magnitude of the vaccine-elicited immune response can be assessed through the diversity of different T-cell receptors and be used as a more accurate method to study T-cell response in future studies and (2) characterize HIV-specific T-cell repertoire over time following vaccination and identify long-lived vaccine elicited T-cell clones with their molecular profile that can be used to further our understanding of the depth of response needed for durable protective immunity. Overall, the proposed research provides an innovative methodology to better understand the vaccine-induced T-cell clonotypic architecture through multi-omics approaches that can further our understanding of the T-cell response needed for HIV-prevention and control.
Program
Doctoral Research Award - Priority Announcement - HIV/AIDS and/or STBBI
Location
Washington, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
477372
Name
Xu Guoyue
Region
Washington
Country
United States of America
Orgtype
Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Characterization of the clonal dynamics of HIV-specific T-cell repertoire from a phase 2b/3 HIV-vaccine efficacy trial
Programtype2
Studentship Programs
Orgnameinp2
Direct Payment
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award - Priority Announcement - HIV/AIDS and/or STBBI
Keyworddelim
Bulk And Single Cell T-Cell Receptor Sequencing; Hiv & Vaccine-Efficacy Trial; Systems Immunology; T-Cell Clonal Dynamics; T-Cell Repertoire
Abstract
With an estimated 1.5 million new cases and 650 000 deaths globally in 2021, human immunodeficiency virus (HIV) infection is a major contributor to the global burden of disease and causes significant burden on healthcare systems in low-resource communities. As such, there is an urgent need for an effective HIV-preventative intervention. One of the major hurdles in HIV-vaccine development is that it is difficult to generate long-lived protective immunity, partly due to the extraordinary genetic diversity of different HIV strains. While the goal of many vaccines is to induce generation of protective antibodies, it has become increasingly clear induction of a strong and durable T-cell mediated response is also important for protection. As more early-stage studies and clinical trials shift back to the development of T-cell based preventative efforts, there is a need to leverage and develop more high-throughput and sensitive immunological approaches to study the vaccine elicited immune response. Using a smaller subset of vaccine participants from a phase 2b/3 HIV-vaccine efficacy trial that took place in Sub-Saharan Africa (HVTN705), this proposal will (1) aim to establish proof-of-concept that the magnitude of the vaccine-elicited immune response can be assessed through the diversity of different T-cell receptors and be used as a more accurate method to study T-cell response in future studies and (2) characterize HIV-specific T-cell repertoire over time following vaccination and identify long-lived vaccine elicited T-cell clones with their molecular profile that can be used to further our understanding of the depth of response needed for durable protective immunity. Overall, the proposed research provides an innovative methodology to better understand the vaccine-induced T-cell clonotypic architecture through multi-omics approaches that can further our understanding of the T-cell response needed for HIV-prevention and control.
Competitiondate
202210
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Xu, Guoyue
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~
Direct Payment - $105,000 Grant (2022-23) | Canada Spends